Supplementary Table 1 from Quantitative ER and PgR Assessment as Predictors of Benefit from Lapatinib in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Year: 2023
Type: supplementary-materials
Abstract: PDF - 66K, This table contains the clinical characterisitcs of patients enrolled in the EGF 30008 trial.
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361908564